Mobile

A clinical study to look at the safety, effectiveness and how COPD patients tolerate a new compound CHF6001 which will be inhaled daily for 28 days compared with existing treatment and placebo

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001005-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of the study are: - to evaluate the effect of CHF 6001 DPI on biological markers of inflammation in induced sputum and in the blood, and on pulmonary function. - to evaluate the safety and tolerability of CHF 6001 DPI after 28 days of inhaled dosing - to assess the blood PK profile of CHF6001 and its metabolite at steady-state in GOLD stage 2-3 COPD patients

Critère d'inclusion

  • The participants of this study have chronic obstructive pulmonary disease (COPD)

Liens